Symbols / LLY
LLY Chart
About
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 980.68B |
| Enterprise Value | 967.67B | Income | 20.64B | Sales | 65.18B |
| Book/sh | 29.66 | Cash/sh | 8.14 | Dividend Yield | 60.00% |
| Payout | 26.14% | Employees | 50000 | IPO | — |
| P/E | 45.34 | Forward P/E | 24.82 | PEG | — |
| P/S | 15.05 | P/B | 35.06 | P/C | — |
| EV/EBITDA | 30.53 | EV/Sales | 14.85 | Quick Ratio | 0.78 |
| Current Ratio | 1.58 | Debt/Eq | 165.31 | LT Debt/Eq | — |
| EPS (ttm) | 22.93 | EPS next Y | 41.88 | EPS Growth | 51.40% |
| Revenue Growth | 42.60% | Earnings | 2026-04-30 | ROA | 19.42% |
| ROE | 101.16% | ROIC | — | Gross Margin | 83.04% |
| Oper. Margin | 44.90% | Profit Margin | 31.67% | Shs Outstand | 943.36M |
| Shs Float | 890.99M | Short Float | 0.88% | Short Ratio | 2.48 |
| Short Interest | — | 52W High | 1133.95 | 52W Low | 623.78 |
| Beta | 0.39 | Avg Volume | 3.27M | Volume | 750.11K |
| Target Price | $1212.82 | Recom | Buy | Prev Close | $1042.15 |
| Price | $1039.56 | Change | -0.25% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$1212.82
Mean price target
2. Current target
$1039.56
Latest analyst target
3. DCF / Fair value
$37.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1039.56
Low
$870.00
High
$1500.00
Mean
$1212.82
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | RBC Capital | — → Outperform | $1250 |
| 2026-02-20 | init | Barclays | — → Overweight | $1350 |
| 2026-02-09 | main | Deutsche Bank | Buy → Buy | $1285 |
| 2026-02-05 | main | JP Morgan | Overweight → Overweight | $1300 |
| 2026-02-05 | main | Cantor Fitzgerald | Overweight → Overweight | $1205 |
| 2026-02-05 | main | Wells Fargo | Overweight → Overweight | $1280 |
| 2026-02-05 | main | Morgan Stanley | Overweight → Overweight | $1313 |
| 2026-01-20 | main | Guggenheim | Buy → Buy | $1161 |
| 2025-12-15 | main | B of A Securities | Buy → Buy | $1268 |
| 2025-12-10 | main | Wells Fargo | Overweight → Overweight | $1200 |
| 2025-12-04 | main | BMO Capital | Outperform → Outperform | $1200 |
| 2025-12-03 | main | Guggenheim | Buy → Buy | $1163 |
| 2025-11-24 | main | Morgan Stanley | Overweight → Overweight | $1290 |
| 2025-11-24 | main | Bernstein | Outperform → Outperform | $1300 |
| 2025-11-19 | main | Truist Securities | Buy → Buy | $1182 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $1150 |
| 2025-11-13 | main | Morgan Stanley | Overweight → Overweight | $1171 |
| 2025-11-12 | main | Citigroup | Buy → Buy | $1500 |
| 2025-11-10 | down | Freedom Capital Markets | Buy → Hold | $950 |
| 2025-11-10 | up | Leerink Partners | Market Perform → Outperform | $1104 |
News
RSS: Latest LLY news- LLY Stock Quote Price and Forecast - CNN Mon, 23 Feb 2026 08
- Is Eli Lilly (LLY) Pricing In GLP 1 Growth After Recent Share Price Pullback - simplywall.st Wed, 25 Feb 2026 14
- Why Eli Lilly Stock Just Popped - The Motley Fool Mon, 23 Feb 2026 15
- Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study - Finviz Wed, 25 Feb 2026 16
- Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA - Stocktwits ue, 24 Feb 2026 21
- Novo Nordisk's Loss Is Eli Lilly's Gain - Yahoo Finance Singapore Wed, 25 Feb 2026 13
- LLY: RBC Capital Initiates Coverage with 'Outperform' Rating | L - GuruFocus Wed, 25 Feb 2026 15
- Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide (NVO:NYSE) - Seeking Alpha Mon, 23 Feb 2026 15
- Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St. hu, 12 Feb 2026 08
- Why Eli Lilly Stock Jumped 40%? - Trefis Sat, 21 Feb 2026 07
- Is Eli Lilly Stock Underperforming the S&P 500? - Barchart.com ue, 24 Feb 2026 06
- Eli Lilly rises as rival obesity-drug trial data strengthen tirzepatide’s edge - Quiver Quantitative Mon, 23 Feb 2026 14
- Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact - Finviz Wed, 25 Feb 2026 16
- Why Eli Lilly Stock Slumped Today - The Motley Fool Wed, 25 Feb 2026 00
- Eli Lilly (LLY) Stock Trades Up, Here Is Why - Yahoo Finance Wed, 04 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 481 | — | — | Stock Gift at price 0.00 per share. | DOZIER ERIC | Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 4 | 4959.0 | — | Stock Award(Grant) at price 1036.05 per share. | SULZBERGER GABRIELLE | Director | — | 2026-02-17 00:00:00 | D |
| 2 | 9 | 9917.0 | — | Stock Award(Grant) at price 1036.05 per share. | FYRWALD J. ERIK | Director | — | 2026-02-17 00:00:00 | D |
| 3 | 15 | 15917.0 | — | Stock Award(Grant) at price 1036.05 per share. | LUCIANO JUAN R | Director | — | 2026-02-17 00:00:00 | D |
| 4 | 11 | 12417.0 | — | Stock Award(Grant) at price 1036.05 per share. | ALVAREZ RALPH | Director | — | 2026-02-17 00:00:00 | D |
| 5 | 207 | nan | — | — | CUSTER KENNETH L | Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 391 | nan | — | — | BROWN ADRIANE S | Officer | — | 2026-02-13 00:00:00 | D |
| 7 | 184 | nan | — | — | ZAKROWSKI DONALD A | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 368 | nan | — | — | MONTARCE LUCAS E | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 4162 | 4348443.0 | — | Stock Award(Grant) at price 1044.67 per share. | YUFFA ILYA | Officer | — | 2026-02-09 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -671.52M | -682.55M | -777.47M | -129.80M |
| TaxRateForCalcs | 0.20 | 0.16 | 0.20 | 0.08 |
| NormalizedEBITDA | 35.09B | 22.95B | 15.72B | 10.22B |
| TotalUnusualItems | -3.39B | -4.14B | -3.87B | -1.56B |
| TotalUnusualItemsExcludingGoodwill | -3.39B | -4.14B | -3.87B | -1.56B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 20.64B | 10.59B | 5.24B | 6.24B |
| ReconciledDepreciation | 2.00B | 1.77B | 1.53B | 1.52B |
| ReconciledCostOfRevenue | 11.05B | 8.42B | 7.08B | 6.63B |
| EBITDA | 31.69B | 18.81B | 11.85B | 8.66B |
| EBIT | 29.70B | 17.04B | 10.32B | 7.14B |
| NetInterestIncome | -605.40M | -312.30M | -268.80M | -314.40M |
| InterestExpense | 780.60M | 485.90M | 331.60M | 339.80M |
| InterestIncome | 175.20M | 173.60M | 62.80M | 25.40M |
| NormalizedIncome | 23.36B | 14.05B | 8.33B | 7.68B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 20.64B | 10.59B | 5.24B | 6.24B |
| TotalExpenses | 35.48B | 28.00B | 23.80B | 20.26B |
| DilutedAverageShares | 899.30M | 904.10M | 903.30M | 950.18M |
| BasicAverageShares | 894.43M | 900.60M | 900.20M | 950.18M |
| DilutedEPS | 22.95 | 11.71 | 5.80 | 6.57 |
| BasicEPS | 23.08 | 11.76 | 5.82 | 6.57 |
| DilutedNIAvailtoComStockholders | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncomeCommonStockholders | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncome | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncomeIncludingNoncontrollingInterests | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | 20.64B | 10.59B | 5.24B | 6.24B |
| TaxProvision | 5.09B | 2.09B | 1.31B | 561.60M |
| PretaxIncome | 25.73B | 12.68B | 6.55B | 6.81B |
| OtherIncomeExpense | -3.96B | -4.36B | -3.77B | -1.21B |
| OtherNonOperatingIncomeExpenses | -571.00M | -219.00M | 97.00M | 358.60M |
| SpecialIncomeCharges | -3.39B | -4.14B | -3.87B | -1.15B |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | 435.00M | 3.80B | 908.50M | 405.20M |
| WriteOff | 484.00M | 861.00M | 68.00M | 244.60M |
| ImpairmentOfCapitalAssets | 236.10M | |||
| RestructuringAndMergernAcquisition | 2.91B | 3.28B | 3.80B | 908.50M |
| GainOnSaleOfSecurity | -49.50M | -20.20M | -410.70M | 176.90M |
| NetNonOperatingInterestIncomeExpense | -605.40M | -312.30M | -268.80M | -314.40M |
| InterestExpenseNonOperating | 780.60M | 485.90M | 331.60M | 339.80M |
| InterestIncomeNonOperating | 175.20M | 173.60M | 62.80M | 25.40M |
| OperatingIncome | 29.70B | 17.04B | 10.32B | 8.28B |
| OperatingExpense | 24.43B | 19.59B | 16.72B | 13.63B |
| ResearchAndDevelopment | 13.34B | 10.99B | 9.31B | 7.19B |
| SellingGeneralAndAdministration | 11.09B | 8.59B | 7.40B | 6.44B |
| GeneralAndAdministrativeExpense | 8.59B | 7.40B | 6.44B | 6.43B |
| OtherGandA | 8.59B | 7.40B | 6.44B | 6.43B |
| SalariesAndWages | -461.70M | -461.90M | -372.90M | -289.70M |
| GrossProfit | 54.13B | 36.62B | 27.04B | 21.91B |
| CostOfRevenue | 11.05B | 8.42B | 7.08B | 6.63B |
| TotalRevenue | 65.18B | 45.04B | 34.12B | 28.54B |
| OperatingRevenue | 65.18B | 45.04B | 34.12B | 28.54B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 50.37M | 50.37M | 50.40M | 450.00K |
| OrdinarySharesNumber | 894.43M | 897.54M | 899.38M | 950.18M |
| ShareIssued | 944.80M | 947.90M | 949.78M | 950.63M |
| NetDebt | 35.23B | 30.38B | 22.41B | 14.17B |
| TotalDebt | 42.50B | 33.64B | 25.23B | 16.24B |
| TangibleBookValue | 14.12B | 2.34B | -1.07B | -629.80M |
| InvestedCapital | 69.04B | 47.92B | 36.00B | 26.89B |
| WorkingCapital | 20.40B | 4.36B | -1.57B | 896.30M |
| NetTangibleAssets | 14.12B | 2.34B | -1.07B | -629.80M |
| CommonStockEquity | 26.54B | 14.27B | 10.77B | 10.65B |
| TotalCapitalization | 67.40B | 42.80B | 29.09B | 25.39B |
| TotalEquityGrossMinorityInterest | 26.54B | 14.27B | 10.86B | 10.78B |
| MinorityInterest | 79.50M | 91.80M | 125.60M | 175.60M |
| StockholdersEquity | 26.54B | 14.27B | 10.77B | 10.65B |
| OtherEquityInterest | -2.99B | -2.98B | -3.01B | -3.01B |
| GainsLossesNotAffectingRetainedEarnings | -2.88B | -4.32B | -4.33B | -3.84B |
| OtherEquityAdjustments | -2.88B | -4.32B | -4.33B | -3.84B |
| TreasuryStock | 49.50M | 44.20M | 50.50M | 52.70M |
| RetainedEarnings | 24.47B | 13.54B | 10.31B | 10.04B |
| AdditionalPaidInCapital | 7.35B | 7.44B | 7.25B | 6.92B |
| CapitalStock | 590.00M | 592.00M | 593.60M | 594.10M |
| CommonStock | 590.00M | 592.00M | 593.60M | 594.10M |
| TotalLiabilitiesNetMinorityInterest | 85.94B | 64.44B | 53.14B | 38.71B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 50.71B | 36.07B | 25.85B | 21.58B |
| OtherNonCurrentLiabilities | 3.97B | 3.48B | 2.24B | 1.82B |
| EmployeeBenefits | 1.30B | 1.44B | 1.31B | 1.95B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.30B | 1.44B | 1.31B | 1.95B |
| TradeandOtherPayablesNonCurrent | 5.88B | 4.06B | 3.85B | 3.71B |
| NonCurrentDeferredLiabilities | 87.30M | 1.73B | ||
| NonCurrentDeferredTaxesLiabilities | 87.30M | 1.73B | ||
| LongTermDebtAndCapitalLeaseObligation | 40.87B | 28.53B | 18.32B | 14.74B |
| LongTermDebt | 40.87B | 28.53B | 18.32B | 14.74B |
| CurrentLiabilities | 35.23B | 28.38B | 27.29B | 17.14B |
| OtherCurrentLiabilities | 8.46B | 6.40B | 3.28B | 2.85B |
| CurrentDebtAndCapitalLeaseObligation | 1.64B | 5.12B | 6.90B | 1.50B |
| CurrentDebt | 1.64B | 5.12B | 6.90B | 1.50B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.38B | 2.09B | 1.65B | 1.06B |
| PayablesAndAccruedExpenses | 22.76B | 14.77B | 15.46B | 11.73B |
| CurrentAccruedExpenses | 17.38B | 11.54B | 11.69B | 8.78B |
| Payables | 5.38B | 3.23B | 3.77B | 2.95B |
| DividendsPayable | 1.35B | 1.17B | 1.02B | 885.50M |
| TotalTaxPayable | 475.10M | 126.90M | ||
| IncomeTaxPayable | 475.10M | 126.90M | ||
| AccountsPayable | 5.38B | 3.23B | 2.60B | 1.93B |
| TotalAssets | 112.48B | 78.72B | 64.01B | 49.49B |
| TotalNonCurrentAssets | 56.85B | 45.98B | 38.28B | 31.46B |
| OtherNonCurrentAssets | 6.99B | 5.72B | 4.99B | 4.34B |
| NonCurrentDeferredAssets | 9.96B | 8.00B | 5.48B | 2.79B |
| NonCurrentDeferredTaxesAssets | 9.96B | 8.00B | 5.48B | 2.79B |
| InvestmentsAndAdvances | 2.80B | 3.22B | 3.05B | 2.90B |
| InvestmentinFinancialAssets | 668.00M | 1.21B | 1.48B | 1.64B |
| HeldToMaturitySecurities | 211.40M | 214.30M | 213.90M | 235.30M |
| AvailableForSaleSecurities | 668.00M | 1.21B | 1.27B | 1.43B |
| LongTermEquityInvestment | 2.13B | 2.01B | 1.57B | 1.26B |
| GoodwillAndOtherIntangibleAssets | 12.42B | 11.94B | 11.85B | 11.28B |
| OtherIntangibleAssets | 6.52B | 6.17B | 6.91B | 7.21B |
| Goodwill | 5.90B | 5.77B | 4.94B | 4.07B |
| NetPPE | 24.67B | 17.10B | 12.91B | 10.14B |
| AccumulatedDepreciation | -12.56B | -11.79B | -11.10B | -10.23B |
| GrossPPE | 37.23B | 28.89B | 24.01B | 20.38B |
| ConstructionInProgress | 13.01B | 8.24B | 5.08B | 2.80B |
| OtherProperties | 13.49B | 11.46B | 10.33B | 9.41B |
| BuildingsAndImprovements | 10.09B | 8.81B | 8.28B | 7.92B |
| LandAndImprovements | 647.00M | 382.00M | 319.80M | 256.60M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 55.63B | 32.74B | 25.73B | 18.03B |
| OtherCurrentAssets | 147.00M | 266.00M | 149.50M | 7.30M |
| PrepaidAssets | 14.31B | 8.34B | 5.54B | 2.95B |
| Inventory | 13.74B | 7.59B | 5.77B | 4.31B |
| InventoriesAdjustmentsAllowances | 62.90M | 102.40M | 8.90M | 34.20M |
| OtherInventories | 43.00M | 63.00M | 102.40M | 8.90M |
| FinishedGoods | 1.93B | 1.22B | 791.70M | 901.20M |
| WorkInProcess | 8.18B | 3.98B | 3.25B | 2.60B |
| RawMaterials | 3.59B | 2.33B | 1.63B | 801.90M |
| Receivables | 20.16B | 13.28B | 11.34B | 8.56B |
| OtherReceivables | 2.40B | 2.27B | 2.25B | 1.66B |
| AccountsReceivable | 17.76B | 11.01B | 9.09B | 6.90B |
| AllowanceForDoubtfulAccountsReceivable | -14.90M | -14.80M | -16.00M | -22.50M |
| GrossAccountsReceivable | 11.02B | 9.11B | 6.91B | 6.70B |
| CashCashEquivalentsAndShortTermInvestments | 7.27B | 3.27B | 2.93B | 2.21B |
| OtherShortTermInvestments | 154.80M | 109.10M | 144.80M | 90.10M |
| CashAndCashEquivalents | 7.27B | 3.27B | 2.82B | 2.07B |
| CashEquivalents | 1.09B | 657.40M | 2.38B | |
| CashFinancial | 1.73B | 1.41B | 1.44B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 5.96B | 414.00M | -3.15B | 4.60B |
| RepurchaseOfCapitalStock | -4.11B | -2.50B | -750.00M | -1.50B |
| RepaymentOfDebt | -778.00M | -664.00M | 0.00 | -1.56B |
| IssuanceOfDebt | 13.17B | 11.42B | 3.96B | 0.00 |
| CapitalExpenditure | -10.85B | -8.40B | -7.39B | -2.99B |
| EndCashPosition | 7.27B | 3.27B | 2.82B | 2.07B |
| BeginningCashPosition | 3.27B | 2.82B | 2.07B | 3.82B |
| EffectOfExchangeRateChanges | 372.00M | -297.00M | 169.00M | -167.60M |
| ChangesInCash | 3.63B | 746.00M | 583.00M | -1.58B |
| FinancingCashFlow | -2.21B | 1.23B | 3.50B | -5.41B |
| CashFlowFromContinuingFinancingActivities | -2.21B | 1.23B | 3.50B | -5.41B |
| NetOtherFinancingCharges | -772.00M | -491.00M | -335.00M | -308.90M |
| CashDividendsPaid | -5.38B | -4.68B | -4.07B | -3.54B |
| CommonStockDividendPaid | -5.38B | -4.68B | -4.07B | -3.54B |
| NetCommonStockIssuance | -4.11B | -2.50B | -750.00M | -1.50B |
| CommonStockPayments | -4.11B | -2.50B | -750.00M | -1.50B |
| NetIssuancePaymentsOfDebt | 8.05B | 8.90B | 8.65B | -62.00M |
| NetShortTermDebtIssuance | -4.34B | -1.85B | 4.69B | 1.50B |
| NetLongTermDebtIssuance | 12.39B | 10.75B | 3.96B | -1.56B |
| LongTermDebtPayments | -778.00M | -664.00M | 0.00 | -1.56B |
| LongTermDebtIssuance | 13.17B | 11.42B | 3.96B | 0.00 |
| InvestingCashFlow | -10.97B | -9.30B | -7.15B | -3.76B |
| CashFlowFromContinuingInvestingActivities | -10.97B | -9.30B | -7.15B | -3.76B |
| NetOtherInvestingChanges | 1.00M | -248.00M | -98.00M | -302.20M |
| NetInvestmentPurchaseAndSale | 319.00M | -303.00M | -223.00M | -244.00M |
| SaleOfInvestment | 964.00M | 374.00M | 508.00M | 463.60M |
| PurchaseOfInvestment | -645.00M | -677.00M | -731.00M | -707.60M |
| NetBusinessPurchaseAndSale | -661.00M | -948.00M | -1.04B | -327.20M |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | -661.00M | -948.00M | -1.04B | -327.20M |
| NetIntangiblesPurchaseAndSale | -2.79B | -2.75B | -2.34B | -1.04B |
| SaleOfIntangibles | 218.00M | 601.00M | 1.60B | 95.80M |
| PurchaseOfIntangibles | -3.01B | -3.35B | -3.94B | -1.13B |
| NetPPEPurchaseAndSale | -7.84B | -5.06B | -3.45B | -1.85B |
| PurchaseOfPPE | -7.84B | -5.06B | -3.45B | -1.85B |
| OperatingCashFlow | 16.81B | 8.82B | 4.24B | 7.59B |
| CashFlowFromContinuingOperatingActivities | 16.81B | 8.82B | 4.24B | 7.59B |
| ChangeInWorkingCapital | -8.09B | -5.38B | -3.06B | -800.00K |
| ChangeInOtherCurrentAssets | -3.45B | -793.50M | 1.52B | |
| ChangeInPayablesAndAccruedExpense | 10.19B | 2.61B | 4.27B | 1.69B |
| ChangeInPayable | 10.19B | 2.61B | 4.27B | 1.69B |
| ChangeInAccountPayable | 10.19B | 2.61B | 4.27B | 1.69B |
| ChangeInTaxPayable | 346.60M | -359.70M | ||
| ChangeInIncomeTaxPayable | 346.60M | -359.70M | ||
| ChangeInPrepaidAssets | -6.61B | -3.33B | -3.45B | -793.50M |
| ChangeInInventory | -4.67B | -2.51B | -1.43B | -599.70M |
| ChangeInReceivables | -7.00B | -2.15B | -2.45B | -299.60M |
| OtherNonCashItems | 3.53B | 4.11B | 4.12B | 1.37B |
| StockBasedCompensation | 626.00M | 646.00M | 629.00M | 371.10M |
| DeferredTax | -1.71B | -2.68B | -2.34B | -2.19B |
| DeferredIncomeTax | -1.71B | -2.68B | -2.34B | -2.19B |
| DepreciationAmortizationDepletion | 2.00B | 1.77B | 1.53B | 1.52B |
| DepreciationAndAmortization | 2.00B | 1.77B | 1.53B | 1.52B |
| OperatingGainsLosses | -180.00M | -224.00M | -1.88B | 263.50M |
| GainLossOnSaleOfPPE | -180.00M | -224.00M | -1.88B | -156.50M |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | 20.64B | 10.59B | 5.24B | 6.24B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LLY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|